Angina (Angina Pectoris) - Pipeline Review, H1 2018

  • ID: 4473285
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angionetics Inc
  • Caladrius Biosciences Inc
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • Sanofi
  • MORE
Angina (Angina Pectoris) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2018, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 2, 2, 1, 3 and 2 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angionetics Inc
  • Caladrius Biosciences Inc
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • Sanofi
  • MORE
Introduction

Report Coverage

Angina (Angina Pectoris) - Overview

Angina (Angina Pectoris) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Angina (Angina Pectoris) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Angina (Angina Pectoris) - Companies Involved in Therapeutics Development

Angionetics Inc

Caladrius Biosciences Inc

G. Pohl-Boskamp GmbH & Co KG

Hemostemix Inc

ID Pharma Co Ltd

Juventas Therapeutics Inc

Kuhnil Pharmaceutical Co Ltd

Sanofi

TSH Biopharm Corporation Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Angina (Angina Pectoris) - Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alferminogene tadenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitroglycerin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranolazine ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-407899 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Angina - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Angina (Angina Pectoris) - Dormant Projects

Angina (Angina Pectoris) - Discontinued Products

Angina (Angina Pectoris) - Product Development Milestones

Featured News & Press Releases

May 08, 2017: FDA Grants Fast Track designation to XyloCor Therapeutics Lead Candidate XC001

Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder

Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program

Apr 01, 2010: Shionogi’s Nitrolingual Pumpspray is Available for Angina Pectoris Patients

Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Angina (Angina Pectoris), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2018

Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2018

Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2018

Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2018

Angina (Angina Pectoris) - Pipeline by ID Pharma Co Ltd, H1 2018

Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics Inc, H1 2018

Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018

Angina (Angina Pectoris) - Pipeline by Sanofi, H1 2018

Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2018

Angina (Angina Pectoris) - Pipeline by ViroMed Co Ltd, H1 2018

Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2018

Angina (Angina Pectoris) - Dormant Projects, H1 2018

Angina (Angina Pectoris) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Angina (Angina Pectoris) - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Angina (Angina Pectoris), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Angionetics Inc
  • Caladrius Biosciences Inc
  • G. Pohl-Boskamp GmbH & Co KG
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • Kuhnil Pharmaceutical Co Ltd
  • Sanofi
  • TSH Biopharm Corporation Ltd
  • ViroMed Co Ltd
  • XyloCor Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll